Combination treatment may affect IOP results.

Article

Using diclofenac sodium 0.1% and latanoprost 0.005% simultaneously could affect intraocular pressure (IOP) in glaucoma patients

Using diclofenac sodium 0.1% and latanoprost 0.005% simultaneously could affect intraocular pressure (IOP) in glaucoma patients, according to a study published in the Journal of Glaucoma.

Dr Rana Sorkhabi et al., Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Iran, studied 22 patients with bilateral primary open angle glaucoma. Each patient was administered latanoprost for 4 weeks.

The patients were given topical diclofenac sodium in one eye and hydroxypropyl methyl cellulose was given in the other. This was completed 4 times a day for a fortnight. IOP was measured 2 weeks after treatment and 2 weeks after stopping other ophthalmic treatments.

The findings revealed additional administration of diclofenac sodium raised mean IOP from 15.73±1.75 to 17.32±2.23 mmHg. Two weeks after patients stopped using additional solutions, IOP was reduced. The control group did not show any significant difference in mean IOP. When co-administrating diclofenac sodium and latanoprost, the possibility of interference should be considered.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.